Paradigm Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Paradigm Biopharmaceuticals has a total shareholder equity of A$33.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$45.0M and A$11.2M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
Interest coverage ratio | n/a |
Cash | AU$33.55m |
Equity | AU$33.80m |
Total liabilities | AU$11.24m |
Total assets | AU$45.04m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PBIG.F's short term assets (A$41.8M) exceed its short term liabilities (A$10.9M).
Long Term Liabilities: PBIG.F's short term assets (A$41.8M) exceed its long term liabilities (A$317.2K).
Debt to Equity History and Analysis
Debt Level: PBIG.F is debt free.
Reducing Debt: PBIG.F had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PBIG.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PBIG.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.4% each year